The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Collagen Solutions applies for European approval after successful ChondroMimetic study Collagen's shares opened 29% higher at 3.49p as the company revealed quantitative three-dimensional magnetic resonance imaging analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage. http://www.proactiveinvestors.co.uk/companies/news/191961 The eight-year study found there was an improvement in patients' clinical symptoms, including alleviation of pain; improved function; and increased activity level. The 'Knee Injury and Osteoarthritis Outcome Score' (KOOS), a well-known and validated patient-reported outcome measure, showed outcomes following the ChondroMimetic procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies, Collagen observed. The regenerative medtech said the study leaves ChondroMimetic positioned as �the only minimally invasive, cost-effective, single-stage treatment that fits within surgeons' current surgical techniques for smaller cartilage defects with eight-year clinical effectiveness and repair quality data�. With more than a million surgical procedures taking place each year in the US and Europe to treat cartilage defects of the knee, the market for ChondroMimetic is enormous; Collagen reckons at least 30-40% of these operations would be suitable for ChondroMimetic. "Based on our first-hand clinical experience with ChondroMimetic and these new results confirming the sustainability of both cartilage regeneration and the improvement in patient outcomes, it is my firm belief that this scaffold has an important place in the treatment of focal chondral lesions as an alternative to microfracture," said L�szl� Hangody, the orthopaedic surgeon who was the principal investigator of the study.
Collagen Solutions sees share price rise following successful ChondroMimetic study 21.02.18 Calculus Capital portfolio company, Collagen Solutions, saw its share price climb by a third to 3.50p this morning after the company revealed a positive outcome from their ChondroMimetic implants study. ChondroMimetic is a product intended for regeneration of cartilage in knees. Cartilage therapy often sees early results after 2 years, however, long term results are less promising and longer term products are less common and often prohibitively expensive. The team are delighted with the results which were from an 8 year study showing regeneration of cartilage over a long and sustainable time period. Video: Jamal Rushdy, chief executive of Collagen Solutions, discusses the results of the study..... https://www.calculuscapital.com/collagen-solutions-share-price-rises-following-successful-chondromimetic-study/
First rule of investing do your own research (DYOR). I invested after reading about collagen sol in the FT weekend, I liked the fact that Directors had made big buys at 5p because I assumed they expected a good return on that. The problem with small shares is that are often illiquid, share prices volatile and they are prey to ramping and shorting. That aside it can also take years and cash to get a product approved. That said, Collagen is not like a biotech, OXB where you need to fund expensive and lengthy trials before getting FDA approval. So optimistic and holding my shares, good luck.
A question for the board , has anybody been invested in a company with so many Hardman research notes. Are we into something special here.
Hardman & Co: Nearing first proprietary product. https://www.investegate.co.uk/collagen-sol-plc--cos-/rns/hardman---co--nearing-first-proprietary-product/201802260715018440F/
In 2015 cos had aims of bein a 100 million pound company by 2020. They made a forecast of earnings of 4.3 million for 2018. There forecasting is very accurate. If the current sp is 4p for an 8 million market cap then 100 million will give a sp in 2020 of approximately 50p. In my opinion this is a reasonable expectation. There has been an enormous increase in the number of knee operations, only slightly behind hips. What collagen's products offer is a reduction in surgery time. One operation rather than two. This is why medical establishments around the world will be buying it. Time in hospital is expensive and any reduction is a cost saving. These products will be sold in Europe, USA and China along with other countries in Asia. Knee replacement is not their only product. Just like N4p which has recently risen I think that COS is also about to go an a positive journey. 6p will soon be in the distant past.
Agreed, a good time to buy.
very good week and cos might be on a few more peoples shopping list. Hopeful this will be a good investment. gla
For those who bought, averaged down and held on well done for your tenacity, have a good weekend.
I see the potential but this needs orders in books. Getting CE mark will be good milestone. tbh needing more than 6p on this lol. All in good time imo.
Tunga in cheek methinks
And this is based on?
Will be up at 6p at end of month😃
See some Col directors toppijng up on their shares. Gotta be good news imo.
So the 500k was Malcolm Gillies , show of confidence from a director is always nice to see.
Personally i think we might see some movement this year. We have this news in Dec Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular, announces its first partnering deal for ChondroMimetic� with a South Korean partner, Insung Medical Co. Ltd. ("Insung Medical"). Financial terms have not been disclosed. And this only last week . This new arrangement is critical to the development of Collagen Solutions' sales and distribution channels within China and is well aligned with the 'Chinese culture' of successfully engaging with partners. We are optimistic regarding the potential to realise growth from this significant market and look forward to providing further updates as they develop." News could drop at any time thats why i'm in.
Totally agree with that. I was in before the 5p fundraiser and have lost a bit but fully expect a return on this. However and agreed not gonna be next week, unless a larger med company jumps on. Company needs to see better sales and profits for this share to rise. Unfortunately this last year or so all funds have i believe went to buying assets like machinery and plant. All will come good imo.
I bought in after seeing the Director Deals in 2017 and doing a little reading on collagen (FT Weekend). I initially lost money, averaged down late last year and yesterday topped up on the good news. I suspect the Directors who purchased shares at 5p will want to see a multiple return on that investment over 5 years so intend to hold for a while yet. They have a substantial interest in getting the sp beyond 5p but that is not going to happen next week imo!.
Interesting trading today and then we get the late reported sell of 500k that had to be a buy . positions now being taken ???
great news
This is the new presentation that he mentions in the interview : http://ir.collagensolutions.com/pdf/presentations/2018/ChondroMimetic-Clinical-Summary-2018.pdf
this is the day we have been waiting on.imo.
If it makes money who cares? Diversification?
This news is more than positive its almost a total cure and it performs better than more expensive treatments. Data highlights � Quantitative 3D MRI analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage. � Improvement in patient clinical symptoms, including pain, function and activity level after treatment sustained over the eight-year period. � The 'Knee Injury and Osteoarthritis Outcome Score' (KOOS), a well-known and validated patient reported outcome measure, showed outcomes following the ChondroMimetic� procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies. Backed by these results ChondroMimetic� is positioned as the only minimally invasive, cost-effective, single-stage treatment that fits within surgeons' current surgical techniques for smaller cartilage defects with eight-year clinical effectiveness and repair quality data.